Humoral and Cellular Immune Response to a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients Taking Belatacept

Transplantation. 2022 May 1;106(5):e264-e265. doi: 10.1097/TP.0000000000004100. Epub 2022 Mar 14.

Authors

Jonathan Mitchell^{1

2}, Jake Kim¹, Jennifer L Alejo¹, Teresa P-Y Chiang¹, Andrew H Karaba³, Joel N Blankson³, Tihitina Y Aytenfisu³, Amy Chang¹, Aura T Abedon¹, Robin K Avery³, Aaron A Tobian³, Allan B Massie^{1

4}, Macey L Levan¹, Daniel S Warren¹, Jacqueline M Garonzik-Wang⁵, Dorry L Segev^{1

4}, William A Werbel³

Affiliations

¹ Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
² Department of Surgery, Howard University College of Medicine, Washington, DC.
³ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
⁴ Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD.
⁵ School of Medicine & Public Health, University of Wisconsin, Madison, WI.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Abatacept / therapeutic use
Antibodies, Viral
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Immunity, Cellular
Kidney Transplantation* / adverse effects
SARS-CoV-2
Transplant Recipients

Substances

Antibodies, Viral
COVID-19 Vaccines
Abatacept

Grants and funding